Explore how AI is transforming the delivery of healthcare and accelerating biomedical research, from optimising clinical workflows to enabling precision medicine. This track showcases the latest AI-driven solutions revolutionising care delivery, pharmaceuticals, and diagnostics.

AI enables faster and more accurate analysis of complex genomic, proteomic, and clinical datasets, powering precision diagnostics and personalised treatment strategies. This session will highlight case studies in oncology, rare diseases, and predictive risk assessment, demonstrating clinical and commercial impact.

Many AI initiatives stall at pilot stage. This panel explores integration, workforce adaptation, procurement, and ROI measurement to ensure AI projects deliver enterprise-wide impact across hospitals, diagnostics, and pharma.

Hospitals are leveraging AI to streamline patient triage, radiology and pathology workflows, and hospital resource allocation. This session explores integration into EMRs, clinician adoption, regulatory validation, and how AI is improving patient outcomes while reducing operational costs.

As hospitals accelerate the adoption of AI, robotics and automation to address workforce challenges, improve operational efficiency and enhance patient care, what does successful implementation really look like? This panel brings together healthcare leaders and technology providers to share practical insights and real-world experiences from deployments in Singapore and across the region. Moving beyond the hype, the discussion will explore the gap between expectations and reality, key lessons from implementation, common barriers to scaling innovation, and what it takes for hospitals and technology partners to successfully translate promising technologies into meaningful healthcare impact.

AI is revolutionising pharmaceutical R&D by improving target identification, compound screening, and trial design, significantly reducing development timelines and costs. This session covers real-world applications, clinical validation, and the regulatory considerations of AI-enabled drug discovery.

ASEAN has the potential to become a healthcare & biomedical AI hub. This panel explore how governments, healthcare institutions, researchers, and industry partners across ASEAN can collaborate to accelerate AI innovation, cross-border partnerships, and the adoption of next-generation healthcare and biomedical solutions across the region.